Elanco Q1 revenue $1.257B, adj EPS $0.45; raises low end of FY guidance

Elanco Animal Health Inc

2023-Q1 EPS reported $0.21 revenue$1,257,000,000

Q1 revenue $1,257M (+3% reported, +6% CC); includes estimated $90-110M benefit from ERP blackout.
Adjusted EPS $0.45 (+25% YoY); reported EPS $0.21 vs $0.10 prior year.
Full year 2023 guidance raised: revenue $4,310-4,400M, adj EPS $0.76-0.83.
Q2 guidance expects revenue $1,003-1,053M due to ERP blackout pull-forward; adj EPS $0.00-0.05.
Net leverage 5.4x; received USDA conditional approval for parvovirus antibody, submitted for IL-31 mAb.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Elanco Animal Health Inc reported financial results for the fiscal quarter ended March 31, 2022.

Period: the fiscal quarter ended March 31, 2022
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated May 9, 2023, announcing the results of operations for the fiscal quarter ended March 31, 2022 and guidance for the full year, first half and second quarter of 2023, for Elanco Animal Health Incorporated.

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-057445

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.